Genetic Analysis AS (NGM: GEAN)

Market Cap	36.90M
Revenue (ttm)	20.71M
Net Income (ttm)	-21.49M
Shares Out	49.38M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	633
Open	0.778
Previous Close	0.776
Day's Range	0.778 - 0.778
52-Week Range	0.259 - 1.681
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market. It offers GA-map Dysbiosis Test Lx, a molecular assay for profiling the gut microbiota to identify and characterize dysbiosis for treating patients with Irritable Bowel Syndrome, Inflammatory Bowel Disease, diabetes type 2, gut disorder, lifestyle diseases, and leaky-gut syndrome; GA-map COVID-19 Fecal Test Kit, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples; GA-m...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 21
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: GEAN

Financial Performance

In 2023, Genetic Analysis AS's revenue was 23.16 million, an increase of 11.65% compared to the previous year's 20.75 million. Losses were -23.82 million, -15.76% less than in 2022.

Financial numbers in NOK